A Randomized, Double-Blind, Placebo-Controlled Trial of Long-Term (2-Year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Trial of Long-Term (2-Year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Galantamine (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 24 Jun 2013 Results presented at the 11th World Congress of Biological Psychiatry.
    • 24 Jun 2013 Primary endpoint 'Mini-Mental-State-Examination' has been met.
    • 05 Dec 2012 Status changed from active, no longer recruiting to discontinued based on information reported in a Janssen Research and Development media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top